# E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy

> **NCT01986764** · NA · WITHDRAWN · sponsor: **University of Pennsylvania**

## Conditions studied

- Planned RRSO

## Interventions

- **DRUG:** Lisdexamfetamine
- **DRUG:** Estradiol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01986764
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-07-01
- **Primary completion:** 2013-07-01
- **Final completion:** 2013-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding was not obtained for this study and no participants were enrolled.
- **Last updated:** 2017-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986764, "E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01986764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*